Search

Displaying results 1451 - 1460 of 7673 in total
  1. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … [L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.

  2. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized … Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy.

  3. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence.

  4. Drug

    Ivermectin

    go.drugbank.com/drugs/DB00602
    ApprovedInvestigationalVet approved

    With the advent of 2020 and the COVID-19 pandemic, ivermectin began garnering notoriety due to its off-label use for the prophylaxis and treatment of COVID-19. … [L31453] Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de

    Mixtures: Eqvalan Duo Oral Paste for Horse
  5. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021. … Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers.

  6. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    [L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047] … [A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.

  7. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United Sta...

  8. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Casimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent … Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.

  9. Drug

    Perflutren

    go.drugbank.com/drugs/DB00556
    ApprovedInvestigational

    The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. … During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.

  10. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    In January 2007, the FDA approved the intravenous administration of azacitidine. … As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis.

    Synonyms: 4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one